五月婷网站,av先锋丝袜天堂,看全色黄大色大片免费久久怂,中国人免费观看的视频在线,亚洲国产日本,毛片96视频免费观看

深圳欣博盛生物科技有限公司
中級會員 | 第5年

13129540117

InVivoKines™體內(nèi)研究專用蛋白:超高活性和穩(wěn)定性

時間:2025/1/24閱讀:140
分享:

細胞因子是一類小蛋白,能在細胞間傳遞信息,具有免疫調(diào)節(jié)和效應(yīng)功能,這些作用使得它們在各種免疫相關(guān)疾病的臨床前和臨床研究中極-具吸引力。它們在免疫中發(fā)揮關(guān)鍵作用,而基于工程化細胞因子的療法代表了免疫治療的新發(fā)展。然而細胞因子的廣泛應(yīng)用受到血液半衰期短、多效性和脫靶效應(yīng)的限制。對細胞因子生物學的深入了解以及創(chuàng)新的細胞因子工程技術(shù)可以應(yīng)對這些限制,但他們通常又無法用于基礎(chǔ)研究。

 

InVivoKines™ 是 AdipoGen Life Sciences利用Knobs-into-Holes (KIH) 技術(shù)研發(fā)的新一代重組融合蛋白,用于免疫治療、臨床前和轉(zhuǎn)化體內(nèi)研究。如需訂購Adipogen公司產(chǎn)品,請聯(lián)系國內(nèi)授權(quán)代理欣博盛生物。

InVivoKines™ 優(yōu)勢與特點:
• 具有天然構(gòu)象——在HEK293或CHO細胞中生產(chǎn)

穩(wěn)定性.png

• 在無動物條件下生產(chǎn)
• 通過ELISA及基于細胞的檢測測試的高生物活性
• 通過SEC驗證的純度和均一性
• 低內(nèi)毒素水平
• 批次間一致性


天然細胞因子與Fc融合(KIH技術(shù))

InVivoKines™ 是使用 Knobs-into-Holes (KIH) 技術(shù)研發(fā) 的Fc融合蛋白

• Fc-KIH技術(shù)允許Fc異源二聚體化,創(chuàng)造出具有兩個不同臂的結(jié)構(gòu),以設(shè)計天然存在的活性單體、異源二聚體或同源二聚體蛋白

• Fc-KIH 域增強了細胞因子的血漿半衰期,從而在保持活性的同時顯著改善藥代動力學(PK)

• Fc-KIH 域與 Fcγ受體(FcγRs)和補體 C1q結(jié)合,可能導(dǎo)致抗體依賴性細胞介導(dǎo)的細胞毒性作用(ADCC)、抗體依賴性細胞介導(dǎo)的吞噬作用(ADCP)和補體依賴的細胞毒性作用(CDC)

• Fc-KIH LALA-PG突變抑制了與FcγRsC1q的結(jié)合,而與FcRn結(jié)合和Fc穩(wěn)定性不受影響

• Fc-KIH 在內(nèi)毒素含量低的哺乳動物細胞中生產(chǎn)

• Fc-KIH 蛋白是為體內(nèi)研開的,但也同樣適用于體外實驗!


AdipoGen Life Sciences利用KIH技術(shù)開發(fā)單體、異源二聚體或同源二聚體Fc融合蛋白.

穩(wěn)定性-1.png

沉默的Fc-KIH(LALA-PG 突變)

AdipoGen Life Sciences利用hIgG1-P329G LALA突變來設(shè)計其沉默的Fc-KIH域,這些突變完-全消除了與FcγRC1q的相互作用,包含了有限數(shù)量的突變,并且不影響FcRn的相互作用和 Fc 的穩(wěn)定性。LALA-PG突變顯示未檢測到與Fc受體或 C1q 的結(jié)合,在基于功能細胞的檢測中無活性,并且不引發(fā)炎癥性細胞因子反應(yīng)。

穩(wěn)定性-2.png

LITERATURE:

•  (1) Knobs-into-Holes (KIH) Technology: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996) 

• (2) Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models: A.F. Labrijn, et al.; Sci. Rep. 7, 2476 (2017) 

• (3) Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions:T. Schlothauer, et al.; Prot. Eng. Design Sel. 29, 457 (2016)

 

單體IL-2蛋白

IL-2 Superkine已被證明能誘導(dǎo) 細胞(CD4/CD8)增殖( T 調(diào)節(jié)細胞),導(dǎo)致細胞毒性CD8 T細胞和NK細胞的顯著擴增,因此,與人IL-2 WT相比,體內(nèi)抗腫瘤反應(yīng)得到改善。IL-2 Superkine(單體):Fc-KIHIL-2 Superkine:Fc(二聚體)更高效,等同于或優(yōu)于金標準 IL-2 Aldesleukin。

IL-2 Superkine (monomeric): Fc-KIH (human)(rec.)

穩(wěn)定性-3.png

AG-40B-022210μg|3x10μg|100μg
NEWIL-2 Superkine H9T (monomeric): Fc-KIH(human) (rec.)
AG-40B-022310μg|3x10μg|100μg
IL-2 (human) (monomeric): Fc-KIH (human) (rec.)
AG-40B-022410μg|3x10μg|100μg
IL-2 (mouse) (monomeric): Fc-KIH (human) (rec.)
AG-40B-022510μg|3x10μg|100μg
FIGURE: IL-2 Superkine (monomeric):Fc-KIH (human) (rec.) (Prod. No. AG-40B-0222)activates the IL-2 receptor better than the dimeric IL-2 Superkine ((Prod. No. AG40B-0111) using the IL-2 Bioass ay (Promega JA2201).


NEW   IL-27 (mouse):Fc-KIH (human) (rec.)      AG-40B-0236

IL-27由兩個亞基IL-27p28和EBI3組成。它促進NK和T細胞增殖以及 IFN-γ 的產(chǎn)生。IL-27對多種病毒具有強大的抗病毒活性,并通過產(chǎn)生抗血管生成趨化因子具有抗腫瘤活性。


IL-27 (mouse):Fc-KIH (human) (rec.)是一種異源二聚體Fc-KIH結(jié)構(gòu)體,與小鼠和人的IL-27R復(fù)合物結(jié)合,激活小鼠和人細胞中Stat3磷酸化。與傳統(tǒng)的二聚體IL-277 (mouse):Fc相比,其活性更強。

穩(wěn)定性-4.png

FIGURE: IL-27 (mouse):Fc-KIH (human) (rec.) (Prod. N o.AG-40B-0236) (Heterodimer)is more active than an IL-27 (mouse):Fc from a competitor (Dimer of Heterodimer)in Stat 3 phosphorylation in HepG2 cells (shown as quantification figure of the westernblot)

 

NEW Fc (LALA-PG)-KIH (human):GDF15 (mouse) (rec.)      AG-40B-0245

GDF15的作用是多方面的,包括對食欲調(diào)節(jié)、代謝、妊娠、細胞存活、免疫反應(yīng)和炎癥的作用。


AdipoGen Life Sciences的Fc (LALAPG)-KIH(human):GDF15(mouse) (rec.)是一種在體內(nèi)研究中具有長效高活性的獨-特蛋白質(zhì),與其他形成無活性大聚集體的經(jīng)典GDF15-Fc蛋白不同,是具有生物活性的同源二聚體。

穩(wěn)定性-5.png

FIGURE: A binding assay shows that Fc (LALA-PG)-KIH (human):GDF15 (mouse) (rec.) (Prod. No. AG-40B-0245) binds with high affinity to its receptor GFRAL (mouse). The Fc (LALA-PG)-KIH(human):GDF15 (mouse) (rec.), which migrates as a dimer by SEC, binds to its receptor mouse GFRAL with an EC50 ~15 ng/ml, while the GDF15 (mouse):Fc (human) (rec.), that migrates asan aggregate by SEC (>1000 kDa), binds similar to the control protein with low affinity.


InVivoKines™?產(chǎn)品目錄

產(chǎn)品名稱貨號結(jié)構(gòu)Fc-KIH 默認
IL-2 (human) (monomeric): Fc-KIH (human) (rec.)AG-40B-0224MonomerNo
IL-2 (mouse) (monomeric): Fc-KIH (human) (rec.)AG-40B-0225MonomerNo
IL-2 Superkine (monomeric): Fc-KIH (human) (rec.)AG-40B-0222MonomerNo
IL-2 Superkine H9T (monomeric): Fc-KIH (human) (rec.)AG-40B-0223MonomerNo
IL-2 (human) (Switch-2) (monomeric): Fc-KIH (human) (rec.)AG-40B-0234MonomerNo
IL-7 (human) (monomeric): Fc-KIH (human) (rec.)AG-40B-0238MonomerNo
IL-7 (human) (monomeric): Fc (LALA-PG)-KIH (human) (rec.) NEWAG-40B-0247MonomerLALA-PG
IL-12 (mouse): Fc-KIH (human) (rec.)AG-40B-0240HeterodimerNo
IL-21 (mouse) (monomeric): Fc (LALA-PG)-KIH (human) (rec.) NEWAG-40B-0250MonomerLALA-PG
IL-23 (mouse): Fc-KIH (human) (rec.)AG-40B-0235HeterodimerNo
IL-23 (mouse): Fc (LALA-PG)-KIH (human) (rec.) NEWAG-40B-0248HeterodimerLALA-PG
IL-27 (mouse): Fc-KIH (human) (rec.)AG-40B-0236HeterodimerNo
IL-27 (mouse): Fc (LALA-PG)-KIH (human) (rec.) NEWAG-40B-0249HeterodimerLALA-PG
IL-33 (oxidation resistant) (human) (monomeric): Fc-KIH (human) (rec.)AG-40B-0233MonomerNo
IL-37 (human) (monomeric): Fc-KIH (human) (rec.)AG-40B-0221MonomerNo
IL-38 (aa 1-152) (human) (monomeric): Fc-KIH (human) (rec.)AG-40B-0241MonomerNo
IL-38 (aa 20-152) (human) (monomeric): Fc-KIH (human) (rec.)AG-40B-0226MonomerNo
IL-38 (aa 3-152) (mouse) (monomeric): Fc-KIH (human) (rec.)AG-40B-0227MonomerNo
Fc (LALA-PG)-KIH (human): GDF15 (mouse) (rec.) NEWAG-40B-0245HomodimerLALA-PG
Fc (LALA-PG)-KIH (human): Irisin (monomeric) (rec.) NEWAG-40B-0246MonomerLALA-PG
Fc-KIH (human) IgG1 Control (rec.)AG-35B-0015ControlNo
Fc (LALA-PG)-KIH (human) IgG1 Control (rec.)AG-35B-0018ControlLALA-PG


InVivoKines™ —可選結(jié)構(gòu)

穩(wěn)定性-6.png


17313129617344465.png

更多詳情,請聯(lián)系A(chǔ)dipoGen中國授權(quán)代理商——欣博盛生物


會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復(fù)您~
撥打電話
在線留言